Aromatic L-amino acid decarboxylase inhibitor
An aromatic L-amino acid decarboxylase inhibitor (synonyms: DOPA decarboxylase inhibitor, DDCI and AAADI) is a drug which inhibits the synthesis of dopamine by the enzyme aromatic L-amino acid decarboxylase (AAAD, or DOPA decarboxylase, DDC).
Peripheral DDCIs incapable of crossing the protective blood-brain-barrier (BBB) are used in augmentation of L-DOPA (Levodopa) in the treatment of Parkinson's disease (PD) to block the peripheral conversion of L-DOPA into dopamine for the purpose of reducing adverse side effects. Combined l-dopa and DDCI therapy does not inherently decrease peripheral cardiovascular side effects of l-dopa administration; however, combined therapy potentiates the central effects of l-dopa by decreasing the dose-dependency 4-5 fold, therein allowing for effective Parkinson's Disease treatment without cardiovascular risk associated with high peripheral dopamine.
List of DDCIs
- Benserazide (Madopar, Prolopa, Modopar, Madopark, Neodopasol, EC-Doparyl, etc.)
- Carbidopa (Lodosyn, Sinemet, Parcopa, Atamet, Stalevo, etc.)
- Methyldopa (Aldomet, Aldoril, Dopamet, Dopegyt, etc.)
- 3',4',5,7-Tetrahydroxy-8-methoxyisoflavone [58262-89-8]
- ↑ "Editorial: Dopa decarboxylase inhibitors". British Medical Journal. 4 (5939): 250–1. November 1974. doi:10.1136/bmj.4.5939.250. PMC 1612227. PMID 4425849.
- ↑ Cotzias, G. C., Papavasiliou, P. S., and Gellene, R., New England Journalof Medicine, 1969, 280, 337.
- ↑ Yahr, M. D., in Advances in Neurology, ed. M. D. Yahr, p. vi, vol. 2. New York, Raven Press, 1973.